Literature DB >> 21560855

Polypoidal choroidal vasculopathy, diagnosis and management.

G Coppens1, L Spielberg, A Leys.   

Abstract

Polypoidal Choroidal Vasculopathy (PCV) was first identified in 1985. Initially considered to be rare, PCV is currently frequently diagnosed in patients of African and Asian descent. In Caucasians, PCV counts for 10% of cases of AMD, and for up to 85% of patients with hemorrhagic or exudative retinal pigment epithelial detachment. Although the clinical presentation can be suggestive, extensive investigation with the indispensable indocyanine green angiography, is required for confirmation of PCV. Treatment has to be considered in active disease threatening the macula. Photodynamic therapy with Verteporfin is required for closure of PCV complexes. Anti-VEGF treatment reduces associated macular edema.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21560855

Source DB:  PubMed          Journal:  Bull Soc Belge Ophtalmol        ISSN: 0081-0746


  8 in total

1.  Angiographic features of transgenic mice with increased expression of human serine protease HTRA1 in retinal pigment epithelium.

Authors:  Sandeep Kumar; Zachary Berriochoa; Balamurali K Ambati; Yingbin Fu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

2.  Detecting abnormalities in choroidal vasculature in a mouse model of age-related macular degeneration by time-course indocyanine green angiography.

Authors:  Sandeep Kumar; Zachary Berriochoa; Alex D Jones; Yingbin Fu
Journal:  J Vis Exp       Date:  2014-02-19       Impact factor: 1.355

3.  Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Shinji Ueno; Piao Chang-Hua; Yasuki Ito; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-18       Impact factor: 3.117

4.  Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy.

Authors:  Sandeep Kumar; Hiroyuki Nakashizuka; Alex Jones; Alyssia Lambert; Xuchen Zhao; Megan Shen; Mackenzie Parker; Shixian Wang; Zachary Berriochoa; Amrita Fnu; Stephanie VanBeuge; Patricia Chévez-Barrios; Mark Tso; Jon Rainier; Yingbin Fu
Journal:  Am J Pathol       Date:  2017-09-21       Impact factor: 4.307

Review 5.  Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.

Authors:  Xinyuan Zhang; Timothy Y Y Lai
Journal:  Biomed Res Int       Date:  2018-02-26       Impact factor: 3.411

6.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

Review 7.  The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.

Authors:  Kelvin Yi Chong Teo; Mark Gillies; Samantha Fraser-Bell
Journal:  Int J Mol Sci       Date:  2018-09-03       Impact factor: 5.923

8.  Periocular triamcinolone acetonide injection for treating polypoidal choroidal vasculopathy concurrent with hemorrhagic retinal detachment.

Authors:  Kaiyan Zhang; Yingying Chen; Xuyang Sun; Qionglei Zhong; Lin Lin; Yuan Gao; Fanlin Hong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.